Kodiak’s Zenkuda Put 54% of Wet AMD Patients on Six-Month Dosing, Four Years After an Extended-Dosing Miss
The molecule that failed on long intervals in 2022 now holds vision with most patients on six-month dosing.
Biologics License Application
Lilly taps InduPro’s proximity-guided platform in up to $950M oncology deal
Eli Lilly and Company has entered a global strategic collaboration, licensing agreement, and equity investment with InduPro Therapeutics, betting up to $950 million on a proximity-guided approach to discover first-in-class bispecific and multispecific oncology therapeutics. Under the agreement, the companies will collaborate on up to three oncology targets, with Lilly also taking an equity stake … Read more
ABL Bio’s Grabody lands record heigh $2.6B deal with Lilly
ABL Bio has signed a major license and research collaboration with Eli Lilly worth up to $2.602 billion, granting access to its Grabody bispecific platform.
Regulatory Roundup: Weekly Insights on Pharma and MedTech—Key Updates from Leading Agencies (December 30th to January 3rd)
Welcome to this week’s Regulatory Insights from Synopulse, featuring the latest updates from the FDA, EMA, and other global regulatory authorities. From groundbreaking drug approvals to critical recalls and new designations, we cover the most significant events driving the pharmaceutical sector. This comprehensive report offers a concise view of the regulatory milestones shaping the pharma, … Read more